---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-003686"
form_type: "8-K/A"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T19:03:08.633289+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD closes Mayne Pharma license deal, appoints new CEO, reports pro forma loss

## Summary
- On Dec 30, 2022, terminated co-CEOs Brian Bernick and Mark Glickman; Glickman eligible for $100k consulting fee plus performance bonuses.
- On Jan 4, 2023, appointed General Counsel Marlan Walker as CEO and Principal Executive Officer.
- Mayne Pharma paid $140M upfront for licenses and assets; plus ~$12.1M for working capital and $1M prepaid royalties.
- Pro forma 2021 net loss of $7.0M, 9mo 2022 net loss of $6.6M; balance sheet shows debt eliminated, cash of ~$128M post-transaction.
- Royalty stream includes 8% on first $80M annual sales, minimum $3M/year for 12 years, and milestone payments up to $30M.

## SEC filing metadata
- accession: 0001193125-23-003686
- form_type: 8-K/A
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/d389338d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-003686
- JSON: https://secwatch.observer/filing/0001193125-23-003686.json
- Plain text: https://secwatch.observer/filing/0001193125-23-003686.txt

## Key facts
- Executive change
  Marlan Walker was appointed as Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On January 4, 2023, the Board appointed Mr. Marlan Walker, the Company’s General Counsel, as the Company’s Chief Executive Officer and Principal Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm
- Executive change
  Mark Glickman was terminated as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: terminated
  - Role: Interim Co-Chief Executive Officer
  source text: On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm
- Executive change
  Brian Bernick was terminated as Interim Co-Chief Executive Officer at TherapeuticsMD, Inc..
  - Action: terminated
  - Role: Interim Co-Chief Executive Officer
  source text: On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.